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Hemophilia A (HA) is an X-linked inherited disorder caused by a defect in the gene encoding coagulation factor VIII (FVIII). The disease is typically divided in three categories of severity based on the circulating levels of pro-coagulant FVIII detected in plasma. HA is "mild" (5-40% of residual FVIII compared with normal plasma), "moderate" (1-5%), or "severe" (<1%). The most efficient strategy to correct or prevent bleeding in the patients relies on the intravenous administration of exogenous therapeutic FVIII that is either plasma derived (pdFVIII) or recombinant (rFVIII). Currently, the most serious complication of FVIII replacement therapy is the development of anti-FVIII antibodies with neutralizing properties that are referred to as "FVIII inhibitors." While anti-drug antibodies typically arise in 1 to 5% of patients, FVIII inhibitors develop in up to 30% of the patients with HA.
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In addition, the intravenous route of administration is classically considered as non-immunogenic. 2 The elevated rate of development of inhibitory antibodies to FVIII is thus intriguing from an immunological standpoint. Here, we will review the current knowledge on the anti-FVIII immune response with a specific focus on the molecular interactions at play in the recognition of FVIII by the cells of the innate and adaptive immune system and on the intuitively proposed risk factors for FVIII alloimmunization. The review will also propose a short summary of the different immuno-intervention approaches validated in preclinical models of HA to confer tolerance to exogenous FVIII.
Dynamics of the anti-FVIII Immune Response
The Primary Immune Response to Therapeutic FVIII
The development of FVIII inhibitors results from a classical allogenic immune response that is dependent on CD4 T cells. 3 The implication of T cells has been suggested empiri-(HIV) infection. 4 It was further suggested by the lack of anamnestic immune response to exogenous FVIII upon treatment using antagonist anti-CD40-ligand (CD40L) antibodies. 5 The mandatory step for initiation of a T cell response is antigen recognition and internalization by professional antigen presenting cells (APCs). After endocytosis, FVIII is cleaved into small peptides that associate with molecules of the major histocompatibility complex of class II (MHC class II) depending on their affinity. The APCs then migrate to secondary lymphoid organs, such as spleen or lymph nodes to reach T cell-rich areas. Complexes of FVIII-derived peptide and MHC class II molecules are exposed at the surface of APCs and are presented to naive CD4 T cells. The recognition of FVIII-derived peptide by the T cell receptor (TCR) of T lymphocytes provides a first activation signal (signal 1). Additional interactions of ligands and receptors at the surface of T cells and APCs (signal 2) and presence of soluble pro-inflammatory stimuli such as cytokines (signal 3) are also required in the microenvironment to activate fully the FVIII-specific naive T cells. Such signals involve at least interactions between CD40L expressed at the T cell surface with CD40 exposed on the APC membrane, 6, 7 as well as CD86
and CD28 expressed by APCs and T cells, respectively (►Fig. 1). 8 Once activated, T cells migrate toward the B cell follicles. In general, humoral responses directed against proteins involve the follicular B cell pathway within secondary lymphoid organs. 9 The early phase of this activation pathway corresponds to an extra-follicular response where naive B cells that have internalized the antigen through their membrane immunoglobulin or B cell receptor (BCR) present complex major histocompatibility class II (CMH II)/peptide complexes to activated T cells. The formation of the T/B cell synapse triggers intracellular signaling that leads to the differentiation of follicular B cells into short-lived plasma cells that produce immunoglobulin M (IgM) or IgG of low affinity. 9, 10 During the late phase of the follicular B cell response, activated B cells re-enter the follicles to interact with follicular helper T cells and form germinal centers (GCs). 9 GCs are specialized microenvironment for T and B cell interactions leading to the proliferation/ selection of B cells and accumulation of somatic hypermutations in the genes encoding the variable regions of the BCRs. GCs responses generate memory B cells that are able to quickly differentiate into antibody secreting cells (ASCs) after re-exposition to the antigen. 11 GCs-associated responses also generate long-lived plasma cells. 12 In the case of anti-FVIII immune responses, the presence of low affinity anti-FVIII antibodies has been documented in healthy donors, nonexposed patients to exogenous FVIII and inhibitor-negative patients. 13, 14 It is conceivable that the production of such low-affinity antibodies results from early extra-follicular responses. In contrast, the finding of high affinity anti-FVIII IgG4 observed in inhibitor-positive patients implicates the differentiation of follicular B cells involving formation of GCs and help from FVIII-specific follicular T cells.
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The Secondary Immune Response to Therapeutic FVIII 24 Of note, the ability of macrophages to express co-stimulation molecules and activate naive CD4 T cells is lower than that of DCs.
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It is important to mention that techniques used to date to validate the role of different splenic APC subsets rely primarily on the physical elimination of the cells, either by targeting cells characterized with a high endocytosis capacity using clodronate-containing liposomes or using depleting antibodies that target particular APC populations. Such approaches are not without consequences on the architecture of the MZ of the spleen 27 and interpretation on whether the targeted APC subtype is at play in the initiation of the anti-FVIII immune response or whether the disrupted MZ splenic structure is an artifactual reason for the reduced onset of FVIII-specific immune responses is not clear. 
Low-Density Lipoprotein Receptor Family
The role of the low-density lipoprotein-1 (LRP-1 or CD91) in FVIII catabolism has been documented in several studies. 
Asialoglycoprotein Receptor
The scavenger receptor asialoglycoprotein receptor (ASGPR) was reported to recognize β-D-galactose and N-acetyl-galactosamine residues that are predominantly exposed on the Bdomain of FVIII. 50 Because no obvious differences in the halflife and immunogenicity of full-length FVIII and B domain deleted-FVIII (BDD-FVIII) have been observed, the role of this receptor in FVIII catabolism or endocytosis by APCs remains to be determined. 51 In agreement with this, the use of galactose to saturate ASGPR had no effect on FVIII uptake by DCs. 
49

CLEC4M
More recently, another C-type lectin receptor, CLEC4M, also known as CD299, L-SIGN, or DC-SIGNR, was reported to bind, internalize and catabolize VWF and FVIII, either in their complex form or not. 32, 66 CLEC4M is expressed by sinusoidal endothelial cells in the liver, placenta, lymph nodes, lung and gastrointestine tractus. 67 As in the case of CD206, the binding of CLEC4M is dependent on high mannose oligosaccharides exposed on FVIII. Since CLEC4M has been mostly described as an adhesion receptor, a direct role of CLEC4M in FVIII immunogenicity is unlikely.
FVIII Residues Involved in Endocytosis
Several attempts have been made to identify the key residues of FVIII implicated in its internalization by APCs, independently from any preconceived idea on the nature of the endocytosis receptors at play. Using the monoclonal antibody KM33 that recognizes an epitope located in the C1 domain of FVIII, Herczenik et al have demonstrated that the Arg2090, Lys2092, and Phe2093 residues are involved in FVIII endocytosis by MO-DCs. 31 The substitution of these residues to alanines by site directed mutagenesis generated a FVIII mutant that is significantly less internalized by APCs.
68,69
More recently, using a similar approach with a monoclonal anti-C2 antibody, we demonstrated that Arg2215 and Arg2220 of the C2 domain also participate in FVIII endocytosis by MO-DCs. 68 The substitution of these residues to Inhibitor
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alanine residues yielded a mutant FVIII that was less prone to endocytosis by MO-DCs. Mutation of the three C1 residues showed conflicting results on the immunogenicity of FVIII in FVIII-deficient mice. 68, 69 Taken together, the available data demonstrate the involvement of complex interaction networks that modulate FVIII uptake and lead either to FVIII catabolism or processing and presentation to T cells.
Facilitation of Endocytosis of FVIII by Other Molecules
The experimental set-up used to study the endocytosis of FVIII by APCs generally leaves aside key proteins that may be directly or indirectly implicated in the internalization process. This is true for VWF and complement molecules which are virtually absent in serum free conditions or are inactivated or present in low amounts when 10% decomplemented fetal calf serum is used. 72 This could explain at least in part the proposed protective effect played by VWF on the immunogenicity of plasma-derived FVIII.
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Molecules of the complement system play major roles in the development of innate and adaptive immune responses. Our group recently investigated the role of the complement system on FVIII endocytosis and presentation to T cells by MO-DCs. We observed that the C3 component of the complement system and its cleavage product C3b increase the endocytosis of FVIII by MO-DCs and its presentation to a FVIII-specific CD4 T cell hybridoma. 74 The interaction of C3b with FVIII was demonstrated by enzyme-linked immunosorbent assay (ELISA), and FVIII and C3b were found to colocalize on the surface of MO-DCs. Interestingly, complement activation restored the endocytosis of the C1 mutant (Arg2090Ala-Lys2092Ala-Phe2093Ala) by MO-DCs. The transient depletion of C3 using humanized cobra venom factor resulted in a drastic reduction of the immune response to exogenous FVIII in FVIII-deficient mice. Furthermore, we observed that the inactive Val634Met FVIII mutant is still immunogenic in FVIII-deficient mice in the absence of activation of the extrinsic coagulation cascade pathway. 82 Thus, whether the pro-coagulant activity of FVIII is a source of the danger signal that triggers the anti-FVIII immune response remains unclear. The inflammatory state of the patients has often been proposed as a potential risk factor to develop FVIII inhibitors. FVIII injection during an infection/surgery or at the time of vaccination has been proposed to increase the risk to develop inhibitors owing to the presence of exogenous or endogenous pro-inflammatory signals.
The hypothesis was strengthened by a pilot study conducted in 26 PUPs treated by early prophylaxis, started at the time of the first bleedings and using lower frequencies and lower doses of FVIII than standard treatment (once 25 IU/kg/ week versus thrice 40-50IU/kg/week for the standard protocol). During the first 20 exposure days, FVIII injections were strictly performed at distance of possible inflammatory events, such as infections, surgery, or vaccinations. 83 The incidence of FVIII inhibitors was significantly reduced compared with an historical control group (48% vs 3.8% study group). These data suggest that injection of exogenous FVIII in a context that avoids danger signals (bleeding, infection, or immunization, etc.) decreases the risk for alloimmunization. This finding was however not reproduced in another cohort of patients, 84 and studies in preclinical models of HA yielded conflicting results. While induction of an acute bleeding in the knee joint of FVIII-deficient mice did not increase the anti-FVIII immune response, 85 bleeding episodes in hemophilic rats increased FVIII immunogenicity. 86 As far as vaccination is concerned, a retrospective analysis on 375 PUPS on the influence of vaccination on inhibitor development reported the absence of association between vaccination and FVIII exposure. 87 Similarly, in humanized hemophilic mice, the injection of vaccinal antigens before FVIII administration decreased the frequency of immunization to exogenous FVIII.
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Several studies reported that intensive FVIII treatment in case of severe hemorrhages or surgery is associated with a higher prevalence of FVIII inhibitor development. 89, 90 As evoked earlier, this could be explained by alert signals inherent to these events, but also to the exposure of the organism to high amounts of FVIII antigens. Indeed, intuitively, the dose of antigen administered is predicted to affect the intensity of the induced immune response. This was demonstrated in the case of FVIII in earlier studies by Reipert et al wherein the intravenous administration of 0.1 or 1 µg rFVIII to FVIII-deficient mice lead to 10-fold different levels of anti-FVIII IgG.
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Interestingly, the use of prophylaxis in HA patients was correlated with a lower risk to develop inhibitors. 83, 89, 90 In principle, prophylaxis, as opposed to on-demand treatment, consists in injecting lower amounts of FVIII at regular intervals independently from the occurrence of bleeding events, to provide an as continuous as possible exposure of the organism to the exogenous FVIII antigen. In line with the antigen discontinuity theory proposed by Pradeu et al, such a continuous exposure to an exogenous antigen should prevent the onset of neutralizing immune responses and favor the induction of a peripheral tolerance.
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Genetic Risk Factors for the Development of an Inhibitory anti-FVIII Immune Response
Among genetic risk factors, the mutation of the F8 gene leading to HA has been established. Thus, mutations resulting in severe alterations of FVIII expression such as the inversion of intron 22, large deletions and nonsense mutations significantly increase the risk to develop inhibitors to therapeutic FVIII. 93 Such mutations lead to the expression of a strongly truncated FVIII or to the complete absence of endogenous FVIII (intron 22 inversion) and the patients with these mutations are referred to as "cross-reactive material" (CRM) negative. From an immunological point of view, the lack of expression of endogenous FVIII in CRM-negative patients results in the absence of thymic education of newly arising T cells and lack of establishment of central tolerance: in absence of FVIII expression in the thymus, FVIII-reactive CD4 T cells are not eliminated during the process of negative selection, and FVIII-specific regulatory T cells (Tregs) are not induced. In contrast, CRM-positive patients have higher chance to develop central tolerance to FVIII and hence to control the immune response to exogenous FVIII. The majority of CRM-positive patients generally produce an endogenous FVIII with a missense point mutation, that is either lacking pro-coagulant activity (e.g., FVIII with the V634M mutation), 94 or that accumulates in the endoplasmic reticulum and is poorly secreted. 95, 96 We and others have documented the importance of the affinity for HLA-DR of the peptides from wild-type therapeutic FVIII that correspond to the peptides of endogenous FVIII that carry the HA-causing mutation, as a risk factor for alloimmunization to therapeutic FVIII. [97] [98] [99] Yet, despite the fact that tolerance is not perfect when a mutated FVIII is expressed, the risk to develop FVIII inhibitors is drastically reduced in CRM-positive patients. Importantly, all CRM-negative patients do not develop inhibitors since inhibitors are detected in roughly 30% of patients with severe HA. The mechanisms involved in the induction of peripheral T cell tolerance to FVIII CRM-negative patients and in the subsequent control of the anti-FVIII immune response have not been elucidated yet. Investigations of the genetic risk factors associated with FVIII inhibitor development suggest the involvement of multiple factors. Polymorphisms in different immune genes, including IL-10, TNF-α, and CTLA-4 genes, have been associated with the onset of FVIII inhibitors. [103] [104] [105] In particular, polymorphisms associated with high Il-10 and TNFα production levels were more frequent among inhibitor-positive patients. 106, 107 Of note, IL-10 was first described to downregulate the synthesis of Th1 cytokines and was associated with polarization of immune responses toward a Th2 type, which are characterized by isotype switch and increased antibody-mediated immune responses. Hu et al reported that proliferating FVIII-specific CD4 T cells exhibit different phenotypes depending on the immune status of the patients. While T cell blasts generated from inhibitor-positive patients were polarized toward both the Th2 (positive for the interleukin Il-4) and Th1 (positive for the cytokine IFN-γ) pathways, T cell blasts obtained from inhibitor-negative patients were of Th1 and Th3 (TGF-β-positive) type. Interestingly, FVIII-specific T cell blasts isolated from healthy donors were polarized either toward the Th1 or Th3 pathways, but never toward Th2.
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The authors proposed that Th1 cells may mostly be implicated in the initiation of anti-FVIII immune response, whereas polarization toward a Th2 response may favor the development of a strong immune response to FVIII with the production of FVIII inhibitors. However, the underlying mechanisms are probably more complex since Il-10, a typical Th2-type cytokine that is also the hallmark of Tregs, is produced by monocytes and is endowed with pleiotropic effects in immunoregulation and inflammation. 
Therapeutic Strategies to Prevent and Control the Anti-FVIII Immune Response
Modification of FVIII Structure
The endocytosis of FVIII being a prerequisite for the onset of the anti-FVIII immune response, a strategy consists in modifying the structure of FVIII to prevent its recognition by APCs. The modification of residues involved in FVIII endocytosis by DCs at the level of the C1 or C2 domains as well as Asn2118 was shown to prevent the uptake of FVIII by human DCs, but did not abrogate the onset of the anti-FVIII immune response in FVIII-deficient mice. 68, 118 Moreover, designing less immunogenic FVIII molecules by introducing mutations may be hardly compatible with the preservation of its structure and pro-coagulant activity. An alternative to the traditional approach of site directed mutagenesis has recently been explored to generate better expressed and possibly less immunogenic FVIII variants. Using ancestral sequence reconstruction (ASR), Zakas et al have recently identified two common FVIII-encoding ancestor genes: An53 from the rodent lineage and An68 from a lineage common to primates and rodents that share 95 and 87% homology with human FVIII sequence, respectively. 119 Recombinant BDD An53 and An68 were more efficiently produced and secreted than human BDD-FVIII. Interestingly, the two ancestor FVIII molecules were also less antigenic than BDD-FVIII as they were poorly recognized and neutralized by a panel of anti-A2 and anti-C2 monoclonal antibodies. Further investigations on T cell epitope prediction as well as immunogenicity in preclinical models of HA are needed to determine whether ASR is a viable strategy to design less immunogenic FVIII in the future. 
Immuno-intervention
Induction of T Cell Tolerance
Drug-mediated immunosuppression has been tested with success in preclinical models of HA. Thus, the daily per os administration to FVIII-deficient mice of rapamycin, an inhibitor of the Il-2 signalization pathway, concomitantly with repeated injections of FVIII was associated with a significant decrease in the anti-FVIII humoral response.
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Rapamycin treatment favored the emergence of CD4 þ CD25 þ Foxp3þ regulatory T cells and down-regulated Th2 polarization. Rapamycin-mediated immunosuppression was however not antigen specific. Recent investigations using Inhibitor Formation in Hemophilia A-An Immunological Perspective Delignat et al. 525
synthetic nanoparticles containing rapamycin and FVIII gave promising results in hemophilic mice. 125 A very brief lowdose regimen of methotrexate has been recently shown to promote tolerance to the human therapeutic enzyme alglucosidase alfa in a mouse model of Pompe disease. Methotrexate-induced tolerance involved the induction of regulatory B cells that secrete Il-10 and TGF-β. 126 The effect of methotrexate in dampening FVIII immunogenicity remains to be tested. Another alternative approach to favor the expansion of Tregs in vivo consists in the use of IL-2/anti-IL-2 antibody (JES6-1) complexes. 127 The administration of this complex in parallel to FVIII treatment during 4 weeks was found to inhibit the production of anti-FVIII antibodies in mice and to induce tolerance in the following weeks. The protective effect was associated with a seven-fold increase in the number of circulating natural CD4 þ CD25 þ Foxp3 þ Helios Tregs, as compared with a control group. The Tregs were however short lived, highly suppressive, but probably not specific for FVIII. In parallel, FVIII-specific human regulatory T cells engineered by retroviral transduction of polyclonal Tregs from healthy donors with an anti-FVIII TCR coding sequence were shown to downregulate anti-FVIII T and B cell responses in vitro. 128 In a different strategy, our group has shown that the injection to pregnant FVIII-deficient mice with the A2 and C2 domains of FVIII fused to the murin Fcγ1 fragment, is followed by the transplacental transfer of A2-Fcγ1 and C2-Fcγ1 to the fetuses. The transfer was dependent on the neonatal Fc receptor and induced central as well as peripheral T cell tolerance that lasted for several weeks after birth.
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Lastly, the induction of FVIII-specific tolerance upon administration of FVIII by the oral route has been investigated. The latter strategy exploits the tolerogenic environment that characterizes the gut-associated lymphoid tissue. The proof of concept was brought with the oral administration of the purified C2 domain of FVIII to FVIII-deficient mice, either by the nasal or oral routes, prior to subcutaneous injection of the C2 domain with adjuvant. 130 However, induction of tolerance using this protocol requires enormous quantities of FVIII and the maintenance of FVIII integrity until it reaches the gut. In an alternative attempt, bioencapsulated FVIII fragments fused to the B subunit of the cholera toxin (CTB), a transmucosal carrier, allowed the absorption of FVIII fragments by gut microbial flora following gavage. The treated mice demonstrated a drastically reduced humoral anti-FVIII response.
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Conclusion
The present days are facing a paradoxical situation where a myriad of different approaches for immuno-intervention and induction of specific tolerance to FVIII are being validated in hemophilic mice, and where novel therapies using bypassing agents or gene therapy may render the administration of exogenous FVIII no longer the standard of care in the future. At the same time, the knowledge we have of the elevated immunogenicity of FVIII in HA patients remains very incomplete and fragmented. Advances in our understanding of the way FVIII is captured and internalized by APCs, of the nature of the dominant T and B cell epitopes, of the major genetic risk factors as well as of the validation or refutation of intuitively proposed danger signals are however undeniable. From both a scientific and clinical points of view, we strongly believe that deciphering the immunogenicity of FVIII should remain a priority for the community. Importantly, the experience accumulated in the field of FVIII and HA shall lead the way in the more general context of immunogenicity of therapeutic proteins.
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